Exisulind

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameExisulind
Drug Alias Name依昔舒林Exisulindum磺基舒林Sulindac SulfoneAposulind +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 5A inhibitors3',5'-cyclic phosphodiesterase inhibitors
Targets3',5'-cyclic phosphodiesterasePhosphodiesterase 5A
Therapy Area/IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPuerto Rico +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOsi Pharmaceutical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUtah State UniversityNational Cancer InstituteAstellas Pharma Inc +[5] 
Active IndicationsN/A
Inactive IndicationsNeoplasm MetastasisProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 

Other Information

ATC CodeN/A
Related LinksWikipedia